Evaluation of Clinical Effect of Acupuncture on Acute Exacerbation of Bronchial Asthma

Evaluation of Clinical Effect of Acupuncture on Acute Exacerbation of Bronchial Asthma Based on Biological Holography Theory

Based on the bioholographic theory, this study preliminarily explores the clinical efficacy of hand acupuncture in treating acute exacerbation of bronchial asthma and evaluates its immediate anti-asthmatic effect, so as to provide a new therapeutic strategy for the clinical management of bronchial asthma.

This study adopted a randomized controlled trial design, with patients in the acute exacerbation phase of bronchial asthma as the research subjects. A total of 72 patients who met the inclusion criteria were randomly divided into the acupuncture group and the control group in a 1:1 ratio. The control group received standard Western medicine treatment, while the acupuncture group was given acupuncture treatment based on biological holography theory in addition to the standard Western medicine treatment. The acupoints selected were Kechuan point, New Kechuan point, and Yuji point. The treatment was administered once a day for 20 minutes each time, for 5 consecutive days, with a 3-month follow-up. The therapeutic efficacy of manual acupuncture in treating acute exacerbation of bronchial asthma was evaluated with indicators including symptom and sign scores, pulmonary function, ACT , mMRC , Mini-AQLQ scale, serum interleukin-4 (IL-4), serum eotaxin and specific immunoglobulin E (SIgE). In addition, the underlying therapeutic mechanism was preliminarily explored to formulate a technical protocol for rapid anti-asthma acupuncture, laying a foundation for long-term and objective efficacy evaluation of this therapy.

Inclusion Criteria:

1. Patients meeting the Western medicine diagnostic criteria for acute exacerbation of bronchial asthma
2. Aged ≥ 18 years old
3. Voluntarily receive treatment and sign the informed consent form

Exclusion Criteria:

1. Those who fail to meet the inclusion criteria
2. Patients suffering from other severe systemic diseases such as diseases of the circulatory system, hematological system and nervous system
3. Pregnant or lactating women
4. Subjects enrolled but not treated per the study protocol
5. Patients who have participated in other clinical trials of medicinal products within 3 months
6. Other circumstances deemed ineligible for enrollment by researchers